Promising data for cancer vaccine INTUVAX in the treatment of kidney cancer
Immunicum AB (publ) presents a status update with promising data from an ongoing clinical phase I/II-study of the cancer vaccine INTUVAX™ in the treatment of metastatic renal cell carcinoma. Two patients with poor prognosis have thus far shown an average survival of about 11 months, which can be compared to the expected median survival of 5 months.05/21/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology | Vaccines